000119312515114999txt 20150401 000119312515114999hdrsgml 20150401 20150401061833 accession number 000119312515114999 conformed submission type sc 14d9a public document count 1 filed date 20150401 date change 20150401 subject company company data company conformed name salix pharmaceutical ltd central index key 0001009356 standard industrial classification pharmaceutical preparation 2834 irs number 943267443 state incorporation de fiscal year end 1231 filing value form type sc 14d9a sec act 1934 act sec file number 00553269 film number 15741280 business address street 1 8510 colonnade center drive city raleigh state nc zip 27615 business phone 919 8621000 mail address street 1 8510 colonnade center drive city raleigh state nc zip 27615 former company former conformed name salix holding ltd date name change 19970807 filed by company data company conformed name salix pharmaceutical ltd central index key 0001009356 standard industrial classification pharmaceutical preparation 2834 irs number 943267443 state incorporation de fiscal year end 1231 filing value form type sc 14d9a business address street 1 8510 colonnade center drive city raleigh state nc zip 27615 business phone 919 8621000 mail address street 1 8510 colonnade center drive city raleigh state nc zip 27615 former company former conformed name salix holding ltd date name change 19970807 sc 14d9a 1 d902900dsc14d9ahtm sc 14d9a sc 14d9a united state security exchange commission washington dc 20549 schedule 14d9 amendment no 7 solicitationrecommendation statement section 14d4 security exchange act 1934 salix pharmaceutical ltd name subject company salix pharmaceutical ltd name person filing statement common stock par value 0001 per share title class security 795435106 cusip number class security william bertrand jr acting chief operating officer executive vice president general counsel salix pharmaceutical ltd 8510 colonnade center drive raleigh north carolina 27615 919 8621000 copy to christopher t cox gregory p patti jr cadwalader wickersham taft llp one world financial center new york ny 10281 212 5046000 name address telephone number person authorized receive notice communication behalf person filing statement ¨ check box filing relates solely preliminary communication made commencement tender offer purpose amendment amendment no 7 this “amendment no 7” amends supplement solicitationrecommendation statement schedule 14d9 salix pharmaceutical ltd the “company” “we” filed security exchange commission the “sec” march 6 2015 a heretofore amended supplemented time time “schedule 14d9” schedule 14d9 relates tender offer sun merger sub inc delaware corporation “purchaser” wholly owned subsidiary valeant pharmaceutical international delaware corporation “vpi” wholly owned subsidiary valeant pharmaceutical international inc british columbia corporation “valeant” acquire outstanding share common stock par value 0001 per share the “shares” company 17300 per share net seller cash without interest le required withholding tax upon term subject condition set forth i offer purchase dated march 4 2015 a amended supplemented time time including amendment supplement offer purchase dated march 17 2015 “offer purchase” ii related letter transmittal accompanied offer purchase which together amendment supplement thereto collectively constitute “offer” offer described tender offer statement schedule a amended supplemented time time filed valeant vpi purchaser sec march 4 2015 the “schedule to” except otherwise set forth below information set forth schedule 14d9 remains unchanged incorporated reference relevant item amendment no 7 capitalized term used defined herein shall meaning assigned term schedule 14d9 amendment no 7 filed reflect certain update set forth below item 8 additional information item 8 “additional information” hereby amended supplemented adding following new subsection end item 8 “final result offer 1200 midnight eastern time wednesday april 1 2015 one minute 1159 pm eastern time march 31 2015 offer expired scheduled extended purchaser advised computershare trust company na capacity depositary offer the “depositary” that expiration offer total 48385169 share excluding share respect notice guaranteed delivery delivered validly tendered properly withdrawn offer representing approximately 7525 share outstanding expiration offer addition depositary advised notice guaranteed delivery delivered respect 8087609 additional share representing approximately 1258 outstanding share expiration offer number share validly tendered withdrawn pursuant offer satisfied minimum condition defined offer purchase condition offer satisfied waived purchaser irrevocably accepted payment expects promptly pay for share validly tendered properly withdrawn offer vpi purchaser expect complete acquisition company april 1 2015 consummating merger pursuant merger agreement accordance section 251h dgcl effective time share outstanding cancelled converted right receive 17300 without interest le applicable withholding tax except share owned valeant vpi purchaser wholly owned subsidiary share held salix wholly owned subsidiary share cancelled retired cease exist consideration delivered exchange therefor following consummation merger share delisted cease trade nasdaq global select market vpi purchaser intend take step cause termination registration share exchange act suspend company’s reporting obligation exchange act promptly practicable april 1 2015 valeant issued press release announcing expiration result offer full text press release attached exhibit a30 hereto incorporated herein reference” item 9 exhibit item 9 schedule 14d9 hereby amended supplemented adding following exhibit exhibit description document a30 press release issued valeant dated april 1 2015 announcing expiration result offer incorporated reference exhibit a5xiii schedule to signature due inquiry best knowledge belief certify information set forth schedule 14d9 true complete correct salix pharmaceutical ltd by s william c bertrand jr dated april 1 2015 name william c bertrand jr title acting chief operating officer executive vice president general counsel